NanoGroup S.A. has adopted a Development Strategy for 2026-2028, with the main goal of achieving a position in the TOP3 of Polish biotechnology groups in terms of market value. The new strategy is designed to build a strong, diversified and financially stable group, minimizing the typical risks of the sector and providing investors with a repeatable mechanism for delivering value.

The strategy’s main goals and objectives until 2028:

• Market leader – being in the TOP 3 of Polish Biotechnology Groups in terms of market value.

• Partnering – signing a minimum of 2 large partnership agreements, representing a source of predictable and recurring revenue.

• Pipeline – active development of a minimum of 10 projects in the Group’s diversified portfolio.

Balanced portfolio and regulatory advantage

• NanoGroup’s portfolio combines disruptive innovations with projects with a faster market path.

• Project Diversification: we want to develop Value Added Medications (VAM), innovation and repurposing projects repurposing i rediscovery. We are active in many registration categories (medicinal products, medical devices and veterinary products), in many therapeutic areas.

• Reduce time and cost: we use simplified regulatory pathways such as FDA 505(b)(2), ODD or MUMS. We reduce time, cost and risk, maximizing return on investment.

Projects and commercialization milestones

Selecting solutions with the possibility of a partnership agreement in a 2-3 year horizon is a key element of the strategy. Thanks to the investment made in Auxilius Pharma, we already have two partnering locomotives today:

• NanOX system – the Group’s largest commercialization potential – an innovative system for extracorporeal kidney perfusion. The optimal time to sign a partnership agreement is late 2026/early 2027. NanOX includes a Class 2b medical device, disposable perfusion set (Class 2a) and perfusion fluid (Class 3).

• AUX-001 – As part of our strategy, we invested in Auxilius Pharma S.A, a Polish leader in the development of Value Added Medicine. In an issue worth a total of PLN 15 million, NanoGroup, through ffVC ASI II, invested PLN 7.5 million, which will be supplemented by a co-investment of another PLN 7.5 million by NCBR Investment Fund ASI S.A.. The funds will enable a Phase 1b clinical trial of the drug AUX-001 for chronic angina. The planned launch in the U.S. market as early as 2029 will be possible through the FDA 505(b)(2) fast track.

Optimize operations and capital management

As a group, we focus on efficiency and transparency in capital allocation:

• rNPV and Rational Allocation – All investment decisions are consistently based on audited rNPV (risk-adjusted net present value) valuation models. This ensures rational value management and supports partnering negotiations.

• Synergies – centralization of administrative and grant support services relieves the burden on researchers, allowing them to fully concentrate their resources on project development and innovation. The approach is one of support, not integration, preserving the research independence of the companies.

“At NanoGroup, we are enhancing investor expectation value with stable financing, a well-diversified project portfolio and a clear strategy focused on rapid partnerships.”
Przemysław Mazurek, CEO of NanoGroup SA.

Zapannounce get with our strategy